Skip to main
COYA
COYA logo

COYA Stock Forecast & Price Target

COYA Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Coya Therapeutics, Inc. is demonstrating promising results with its clinical-stage product COYA 302, which reportedly shows safety and greater efficacy than current treatments in upcoming Phase 2 trials. The positive feedback from key opinion leaders on the anti-inflammatory effects of low-dose IL-2 supports the potential success of this therapy, particularly in treating Alzheimer's disease patients when combined with semaglutide. Additionally, the strong clinical benefits observed in the planned Phase 2 ALS study could pave the way for potential regulatory approval, further enhancing the company's growth prospects in the biotechnology sector.

Bears say

Coya Therapeutics Inc is navigating several critical challenges that contribute to a negative outlook on its stock, primarily stemming from its vulnerability to unexpected outcomes or safety signals during clinical trials. The company is also exposed to regulatory uncertainties that could impact the approval and commercialization of its product candidates, complicating its operational landscape. Furthermore, the combination of increasingly complex and price-sensitive market conditions could hinder the potential profitability of its therapies, making financial forecasting and sustainability a concern.

COYA has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Coya Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Coya Therapeutics Inc (COYA) Forecast

Analysts have given COYA a Strong Buy based on their latest research and market trends.

According to 5 analysts, COYA has a Strong Buy consensus rating as of Nov 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Coya Therapeutics Inc (COYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.